MYRIAD GENETICS, INC.

Lobbying for MYRIAD GENETICS, INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $290,000.00 expenses · posted Apr 18, 2025

Lobbying activity 2

Medicare/Medicaid

Congressional oversight of Medicare Advantage and prior authorization misuses.

Insurance

Commercial coverage decisions impacting biomarker testing in mental health.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.